Medtronic plc (BIT:1MDT)
Italy
· Delayed Price · Currency is EUR 75.94
+1.03 (1.37%)
At close: Jun 6, 2025, 5:30 PM CET
Revenue by Product
Fiscal year is May - April.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Apr '25 Apr 25, 2025 | Apr '24 Apr 26, 2024 | Apr '23 Apr 28, 2023 | Apr '22 Apr 29, 2022 | Apr '21 Apr 30, 2021 | 2013 - 2020 |
| Cardiac Rhythm & Heart Failure | 6.39B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cardiac Rhythm & Heart Failure Growth | 6.61% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diabetes | 2.76B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diabetes Growth | 10.73% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Structural Heart & Aortic | 3.55B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Structural Heart & Aortic Growth | 5.84% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Coronary & Peripheral Vascular | 2.54B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Coronary & Peripheral Vascular Growth | 2.34% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cranial & Spinal Technologies | 4.97B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cranial & Spinal Technologies Growth | 4.58% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Specialty Therapies | 2.94B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Specialty Therapies Growth | 1.27% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Neuromodulation | 1.93B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Neuromodulation Growth | 10.71% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Surgical & Endoscopy | 6.50B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Surgical & Endoscopy Growth | -0.15% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Acute Care & Monitoring | 1.91B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Acute Care & Monitoring Growth | 0.05% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Segment | 48.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Segment Growth | -37.56% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is May - April.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2019 |
|---|---|---|---|---|---|
Period Ending | Apr '24 Apr 26, 2024 | Apr '23 Apr 28, 2023 | Apr '22 Apr 29, 2022 | Apr '21 Apr 30, 2021 | 2012 - 2019 |
| Cardiovascular Operating Profit |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cardiovascular Operating Profit Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Neuroscience Operating Profit |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Neuroscience Operating Profit Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical Surgical Operating Profit |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical Surgical Operating Profit Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diabetes Operating Profit |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diabetes Operating Profit Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is May - April.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Apr '25 Apr 25, 2025 | Apr '24 Apr 26, 2024 | Apr '23 Apr 28, 2023 | Apr '22 Apr 29, 2022 | Apr '21 Apr 30, 2021 | 2013 - 2020 |
| U.S. | 17.17B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| U.S. Growth | 3.67% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Non-U.S. Developed Markets | 10.20B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Non-U.S. Developed Markets Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Emerging Markets | 6.20B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Emerging Markets Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other
Fiscal year is May - April.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Apr '25 Apr 25, 2025 | Apr '24 Apr 26, 2024 | Apr '23 Apr 28, 2023 | Apr '22 Apr 29, 2022 | Apr '21 Apr 30, 2021 | 2013 - 2020 |
| Total Organic Revenue Growth | 4.90% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cardiovascular Organic Revenue Growth | 6.30% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Neuroscience Organic Revenue Growth | 5.20% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical Surgical Organic Revenue Growth | 0.80% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diabetes Organic Revenue Growth | 11.50% |
Log In |
Log In |
Log In |
Log In | Upgrade
|